Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Zaini, Mohamad A.; Mueller, Christine; de Jong, Tristan V. et al.
A p300 and SIRT1 Regulated Acetylation Switch of C/EBP alpha Controls Mitochondrial FunctionCELL REPORTS. Bd. 22. H. 2. 2018 S. 497-511
Schmidt, Marcus; Decker, Thomas; Fehm, Tanja et al.
A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus ) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetroCANCER RESEARCH. Bd. 78. H. 4. 2018
Coombes, R. C.; Tovey, Holly; Kilburn, Lucy et al.
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial)CANCER RESEARCH. Bd. 78. H. 4. 2018
Neitzel, C.; Stroh, S.; Nagel, G. et al.
A promising building block in the chemotherapy of colorectal cancer: The first-in-class mitochondrial disruptor CPI-613NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. Bd. 391. 2018 S. S58-S58
Mueller, V.; Park-Simon, T. -W.; Huober, J. et al.
A randomized, double-blinded pivotal study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. unresectable locally advanced or metastatic breast cancer: HER2CLIMBONCOLOGY RESEARCH AND TREATMENT. Bd. 41. 2018 S. 28-28
Abou-Alfa, Ghassan K.; Chan, Stephen Lam; Furuse, Junji et al.
A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 36. H. 15. 2018
Loibl, Sibylle; Barinoff, Jana; Seiler, Sabine et al.
A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)CANCER RESEARCH. Bd. 78. H. 4. 2018
Heimes, Anne-S.; Jaekel, J.; Weyer-Elberich, V. et al.
A retrospective analysis of immunohistochemically determined IRF4 expression in a consecutive cohort of 114 ovarian cancer patientsONCOLOGY RESEARCH AND TREATMENT. Bd. 41. 2018 S. 92-92
Zhu, Andrew X.; Galle, Peter R.; Kudo, Masatoshi et al.
A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).JOURNAL OF CLINICAL ONCOLOGY. Bd. 36. H. 4. 2018
Paschka, Peter; Schlenk, Richard F.; Weber, Daniela et al.
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialLEUKEMIA. Bd. 32. H. 7. 2018 S. 1621-1630